{"id":4514,"date":"2026-03-17T12:35:14","date_gmt":"2026-03-17T11:35:14","guid":{"rendered":"https:\/\/www.we4cr.com\/?p=4514"},"modified":"2026-03-24T12:28:06","modified_gmt":"2026-03-24T11:28:06","slug":"pmcf-mdr-medical-devices","status":"publish","type":"post","link":"https:\/\/www.we4cr.com\/it\/pmcf-mdr-medical-devices\/","title":{"rendered":"PMCF nell\u2019ambito dell'MDR: da obbligo normativo a vantaggio competitivo"},"content":{"rendered":"<p class=\"wp-block-paragraph translation-block\">In molte aziende di dispositivi medici, la <strong>Post-Market Clinical Follow-up (PMCF)<\/strong> \u00e8 ancora visto come un onere \u2014 un requisito burocratico introdotto dal <strong>Regolamento (UE) MDR (UE 2017\/745)<\/strong> che aggiunge costi e pressione a team regolatori gi\u00e0 sovraccarichi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Questa visione \u00e8 sempre pi\u00f9 miope.<br>Le aziende che trattano il PMCF esclusivamente come un adempimento normativo stanno perdendo una significativa opportunit\u00e0 strategica.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">L'MDR ha cambiato il ciclo di vita delle evidenze cliniche<\/h2>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Una delle modifiche pi\u00f9 importanti introdotte dall'MDR \u00e8 che <strong>le evidenze cliniche non terminano pi\u00f9 con l'approvazione per la commercializzazione<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Nell'ambito del precedente quadro normativo, i produttori potevano spesso fare affidamento su <strong>dichiarazioni di equivalenza e sorveglianza passiva<\/strong>. Oggi, l'MDR richiede la generazione proattiva e continua di dati clinici post-commercializzazione per tutta la durata di vita del dispositivo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Il PMCF, definito nell\u2019articolo 83 e nell\u2019allegato XIV Parte B, non \u00e8 una singola attivit\u00e0 ma un <strong>sistema continuo di evidenze<\/strong>. I suoi output alimentano molteplici documenti normativi, tra cui il <strong>Clinical Evaluation Report (CER)<\/strong>, il <strong>Risk Management File<\/strong> e il <strong>Periodic Safety Update Report (PSUR)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">I documenti di orientamento come <strong>MDCG 2020-7<\/strong> (Modello di Piano PMCF) e <strong>MDCG 2020-6<\/strong> (Valutazione Clinica) chiariscono che il PMCF \u00e8 una parte integrante del quadro delle evidenze cliniche.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">La vera questione per i produttori non \u00e8 pi\u00f9 <em>se<\/em> condurre il PMCF.<br>\u00c8 <strong>come progettarlo in modo da generare evidenze cliniche significative e difendibili.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Perch\u00e9 molti piani PMCF falliscono<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nella pratica, molti piani PMCF presentano le stesse debolezze strutturali.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Gli obiettivi sono spesso <strong>generici<\/strong>, ripetendo il linguaggio normativo anzich\u00e9 affrontare il dispositivo specifico. Dichiarazioni come <em>\"confermare la sicurezza a lungo termine\"<\/em> compaiono frequentemente senza definire esiti clinici misurabili, orizzonti temporali o soglie di accettazione.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anche i metodi sono frequentemente insufficienti. Revisioni della letteratura e sondaggi agli utenti vengono talvolta proposti anche per dispositivi ad alto rischio, dove questi approcci da soli raramente soddisfano le aspettative dell'MDR.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le conseguenze sono prevedibili: richieste di chiarimenti da parte degli Organismi Notificati, ritardi nella certificazione o programmi PMCF che generano dati troppo deboli per supportare aggiornamenti futuri del CER.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">L'industria sta sempre pi\u00f9 vedendo che <strong>i dati pre-commercializzazione da soli non sono pi\u00f9 sufficienti<\/strong>. Le evidenze cliniche devono evolvere continuamente dopo la commercializzazione.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Costruire una strategia PMCF scientificamente solida<\/h2>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Un piano PMCF efficace inizia con un'<strong>analisi strutturata delle lacune<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I produttori devono identificare cosa \u00e8 gi\u00e0 noto dagli studi pre-commercializzazione, quali incertezze rimangono e quali domande devono essere affrontate tramite dati post-commercializzazione.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le lacune comuni includono:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>esiti di sicurezza a lungo termine<\/li>\n\n\n\n<li class=\"translation-block\">prestazioni del dispositivo in <strong>contesti clinici reali<\/strong><\/li>\n\n\n\n<li>eventi avversi rari non rilevabili nelle sperimentazioni pre-commercializzazione<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Da questa analisi, il piano PMCF dovrebbe definire <strong>obiettivi specifici e misurabili<\/strong> legati a esiti clinicamente rilevanti per la popolazione e l'indicazione prevista del dispositivo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">La selezione dei metodi dipende quindi dalla <strong>classe di rischio del dispositivo e dal livello di evidenza richiesto<\/strong>.<br>Per i dispositivi <strong>Classe III<\/strong>, sono spesso necessari studi PMCF dedicati con raccolta di dati grezzi. Per alcuni dispositivi <strong>Classe IIb<\/strong>, fonti di dati real-world strutturate, come i registri delle malattie, possono fornire evidenze sufficienti se il disegno dello studio \u00e8 rigoroso.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">La fattibilit\u00e0 conta tanto quanto la metodologia<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il rigore scientifico deve essere bilanciato con la fattibilit\u00e0 operativa.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Impegni PMCF eccessivamente ambiziosi, come l'arruolamento di centinaia di pazienti in un breve lasso di tempo per un'indicazione rara, si rivelano spesso irrealistici. Quando i piani non possono essere eseguiti, i produttori affrontano <strong>dati mancanti, controlli normativi e potenziali rischi di non conformit\u00e0<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Una strategia PMCF solida richiede quindi sia <strong>forza metodologica che realismo operativo<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ampliare il ruolo dei dati real-world<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il MDR consente ai produttori di utilizzare un intervallo pi\u00f9 ampio di fonti di evidenze post-commercializzazione, tra cui:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>studi di coorte prospettici o retrospettivi<\/li>\n\n\n\n<li>registri delle malattie<\/li>\n\n\n\n<li class=\"translation-block\">analisi di dati da <strong>Cartelle Cliniche Elettroniche<\/strong><\/li>\n\n\n\n<li>sondaggi strutturati agli utenti e revisioni sistematiche della letteratura<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Per determinate aree terapeutiche, in particolare oncologia o cardiologia, i registri consolidati possono fornire preziose <strong>evidenze real-world<\/strong> se la raccolta dati \u00e8 adeguatamente integrata nella strategia PMCF.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Nuove sfide per i dispositivi digitali e abilitati all'IA<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Per i <strong>dispositivi medici software e abilitati all'IA<\/strong>, il PMCF introduce complessit\u00e0 aggiuntive.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Le prestazioni possono evolvere nel tempo a causa di <strong>aggiornamenti software, cambiamenti nel comportamento degli utenti o variazioni nelle distribuzioni dei dati in ingresso<\/strong>. Le strategie PMCF per questi dispositivi devono quindi includere un <strong>monitoraggio continuo delle prestazioni<\/strong>, non solo valutazioni episodiche di sicurezza.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">PMCF come asset strategico<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Quando progettato adeguatamente, il PMCF fa molto di pi\u00f9 che mantenere la conformit\u00e0 normativa.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">I dati clinici post-commercializzazione dimostrano che un dispositivo performa efficacemente <strong>nella pratica clinica reale<\/strong>, rafforzando le discussioni con ospedali, comitati di procurement e organismi di valutazione delle tecnologie sanitarie. Possono supportare negoziazioni di rimborso, abilitare nuove indicazioni cliniche e identificare precocemente segnali di sicurezza emergenti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">In questo senso, un programma PMCF ben progettato diventa <strong>una piattaforma di evidenze real-world<\/strong>, non solo un esercizio normativo.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Da conformit\u00e0 a vantaggio competitivo<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Il PMCF sotto il MDR \u00e8 troppo complesso e troppo rilevante strategicamente per essere trattato come un compito normativo di routine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Le aziende che lo affrontano con rigore metodologico stanno costruendo un <strong>asset di evidenze a lungo termine<\/strong>.<br>Quelle che lo trattano come un obbligo burocratico rischiano di accumulare un <strong>gap di evidenze<\/strong> che alla fine rallenter\u00e0 il progresso normativo e l'espansione sul mercato.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">La differenza sta nella prospettiva:<br><strong>Il PMCF non \u00e8 pi\u00f9 solo conformit\u00e0. Si tratta di costruire le evidenze cliniche che sostengono il dispositivo per tutto il suo ciclo di vita.<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>In many medical device companies, Post-Market Clinical Follow-up (PMCF) is still seen as a burden \u2014 a bureaucratic requirement introduced by the EU MDR (EU 2017\/745) that adds cost and pressure to already overloaded regulatory teams. That view is increasingly short-sighted.Companies that treat PMCF purely as compliance are missing a significant strategic opportunity. The MDR [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4551,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[47],"tags":[89],"class_list":["post-4514","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-pmcf"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PMCF MDR Medical Devices: Turn Compliance Into Advantage<\/title>\n<meta name=\"description\" content=\"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.we4cr.com\/it\/pmcf-mdr-medical-devices\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PMCF MDR Medical Devices: Turn Compliance Into Advantage\" \/>\n<meta property=\"og:description\" content=\"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.we4cr.com\/it\/pmcf-mdr-medical-devices\/\" \/>\n<meta property=\"og:site_name\" content=\"We4 Clinical Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/we4cr\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T11:35:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T11:28:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"designer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"designer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/\"},\"author\":{\"name\":\"designer\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#\\\/schema\\\/person\\\/f2994d482d7d77bd0f01ecf402aced93\"},\"headline\":\"PMCF under MDR: from regulatory obligation to competitive advantage\",\"datePublished\":\"2026-03-17T11:35:14+00:00\",\"dateModified\":\"2026-03-24T11:28:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/\"},\"wordCount\":806,\"publisher\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg\",\"keywords\":[\"PMCF\"],\"articleSection\":[\"News\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/\",\"url\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/\",\"name\":\"PMCF MDR Medical Devices: Turn Compliance Into Advantage\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg\",\"datePublished\":\"2026-03-17T11:35:14+00:00\",\"dateModified\":\"2026-03-24T11:28:06+00:00\",\"description\":\"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/pmcf-mdr-medical-devices\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.we4cr.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PMCF under MDR: from regulatory obligation to competitive advantage\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#website\",\"url\":\"https:\\\/\\\/www.we4cr.com\\\/\",\"name\":\"We4 Clinical Research\",\"description\":\"Inspired by Innatin\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.we4cr.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#organization\",\"name\":\"We4ClinicalResearch\",\"url\":\"https:\\\/\\\/www.we4cr.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/we4cr_logo-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.we4cr.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/we4cr_logo-1.jpg\",\"width\":600,\"height\":79,\"caption\":\"We4ClinicalResearch\"},\"image\":{\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/we4cr\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/we4-clinical-research\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.we4cr.com\\\/#\\\/schema\\\/person\\\/f2994d482d7d77bd0f01ecf402aced93\",\"name\":\"designer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g\",\"caption\":\"designer\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PMCF MDR Medical Devices: Turn Compliance Into Advantage","description":"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.we4cr.com\/it\/pmcf-mdr-medical-devices\/","og_locale":"it_IT","og_type":"article","og_title":"PMCF MDR Medical Devices: Turn Compliance Into Advantage","og_description":"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.","og_url":"https:\/\/www.we4cr.com\/it\/pmcf-mdr-medical-devices\/","og_site_name":"We4 Clinical Research","article_publisher":"https:\/\/www.facebook.com\/we4cr","article_published_time":"2026-03-17T11:35:14+00:00","article_modified_time":"2026-03-24T11:28:06+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg","type":"image\/jpeg"}],"author":"designer","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"designer","Tempo di lettura stimato":"4 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#article","isPartOf":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/"},"author":{"name":"designer","@id":"https:\/\/www.we4cr.com\/#\/schema\/person\/f2994d482d7d77bd0f01ecf402aced93"},"headline":"PMCF under MDR: from regulatory obligation to competitive advantage","datePublished":"2026-03-17T11:35:14+00:00","dateModified":"2026-03-24T11:28:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/"},"wordCount":806,"publisher":{"@id":"https:\/\/www.we4cr.com\/#organization"},"image":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#primaryimage"},"thumbnailUrl":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg","keywords":["PMCF"],"articleSection":["News"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/","url":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/","name":"PMCF MDR Medical Devices: Turn Compliance Into Advantage","isPartOf":{"@id":"https:\/\/www.we4cr.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#primaryimage"},"image":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#primaryimage"},"thumbnailUrl":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg","datePublished":"2026-03-17T11:35:14+00:00","dateModified":"2026-03-24T11:28:06+00:00","description":"PMCF MDR medical devices: turn compliance into advantage with real-world evidence and stronger clinical data.","breadcrumb":{"@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#primaryimage","url":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg","contentUrl":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2026\/03\/medical-team-working-analyzed-the-results-of-medic-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.we4cr.com\/pmcf-mdr-medical-devices\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.we4cr.com\/"},{"@type":"ListItem","position":2,"name":"PMCF under MDR: from regulatory obligation to competitive advantage"}]},{"@type":"WebSite","@id":"https:\/\/www.we4cr.com\/#website","url":"https:\/\/www.we4cr.com\/","name":"We4 Clinical Research","description":"Inspired by Innatin","publisher":{"@id":"https:\/\/www.we4cr.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.we4cr.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.we4cr.com\/#organization","name":"We4ClinicalResearch","url":"https:\/\/www.we4cr.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.we4cr.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2025\/09\/we4cr_logo-1.jpg","contentUrl":"https:\/\/www.we4cr.com\/wp-content\/uploads\/2025\/09\/we4cr_logo-1.jpg","width":600,"height":79,"caption":"We4ClinicalResearch"},"image":{"@id":"https:\/\/www.we4cr.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/we4cr","https:\/\/www.linkedin.com\/company\/we4-clinical-research\/"]},{"@type":"Person","@id":"https:\/\/www.we4cr.com\/#\/schema\/person\/f2994d482d7d77bd0f01ecf402aced93","name":"designer","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1c3d4a50d73adbbaa24d26ad50e7d5065c8071989bb18f6b6b8eaf6d1c4360c0?s=96&d=mm&r=g","caption":"designer"}}]}},"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"We4 Clinical Research","distributor_original_site_url":"https:\/\/www.we4cr.com\/it","push-errors":false,"_links":{"self":[{"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/posts\/4514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/comments?post=4514"}],"version-history":[{"count":1,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/posts\/4514\/revisions"}],"predecessor-version":[{"id":4516,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/posts\/4514\/revisions\/4516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/media\/4551"}],"wp:attachment":[{"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/media?parent=4514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/categories?post=4514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.we4cr.com\/it\/wp-json\/wp\/v2\/tags?post=4514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}